Navigation Links
Warner Chilcott to Present at the Goldman Sachs Leveraged Finance Healthcare Conference
Date:3/4/2011

DUBLIN, Ireland, March 4, 2011 /PRNewswire/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that its Executive Vice President and Chief Financial Officer Paul Herendeen is scheduled to speak at the Goldman Sachs Leveraged Finance Healthcare Conference on Tuesday, March 8th at 12:35 p.m. ET.  

The presentation will be simultaneously webcast at http://ir.wcrx.com/events.cfm, with an archived replay of the webcast available shortly thereafter at http://ir.wcrx.com/events.cfm.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare, gastroenterology, dermatology and urology segments of the North American and Western European pharmaceuticals markets.  The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products.  WCRX-G


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Warner Chilcott Seeks to Refinance its Existing Credit Agreement
2. Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2010
3. Warner Chilcott to Present at the Citi 2011 Global Health Care Conference
4. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2010 Financial Results
5. Warner Chilcott to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. Warner Chilcott to Present at the Bank of America Merrill Lynch Credit Conference
7. Warner Chilcott Announces FDA Approval of New Oral Contraceptive
8. Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
9. Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
10. TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
11. Warner Chilcott Announces FDA Approval of Next Generation Actonel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):